<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00992108</url>
  </required_header>
  <id_info>
    <org_study_id>8295968</org_study_id>
    <nct_id>NCT00992108</nct_id>
  </id_info>
  <brief_title>Efficacy of Botulinum Toxin Versus Lidocaine in Treating Masticatory Myofascial Face Pain Using Ultrasound and EMG Guided Techniques</brief_title>
  <official_title>Efficacy of Botulinum Toxin Versus Lidocaine in Treating Masticatory Myofascial Face Pain Using Ultrasound and EMG Guided Techniques</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Botulinum toxin-A (BTX-A) prevents the release of acetylcholine in presynaptic terminals of
      the neuromuscular junction. It has been proposed to be effective in spastic conditions of the
      head and neck including oromandibular dystonias, bruxism, and muscular hypertrophy (1,2,3,4).
      However, only one randomized, double-blinded, placebo controlled trial has been completed
      involving 20 patients demonstrating both objective and subjective improvement in the BTX-A
      treated group over those treated with saline at one week, one month, and six months (5).

      Currently, in most orofacial pain practices, when the diagnosis of masticatory myofascial
      pain in the head region is made, patients are treated with a standard myofascial protocol.
      This protocol involves stretching, application of moist heat, spray and stretch, and
      lidocaine trigger point injections into the masticatory muscles. This is considered the
      standard of care among most orofacial pain practioners.

      There have been no randomized, double-blinded, head-to-head trials comparing BTX-A injections
      to lidocaine injections in the treatment of masticatory myofacial pain. Moreover, in all
      studies, muscles were targeted using surface landmarks with no confirmatory tests to
      guarantee the medication was administered to the intended muscle. In previous studies, the
      medial and lateral pterygoid muscles, important masticatory muscles that is often hyperactive
      in masticatory myofacial pain was not injected due to lack of palpable surface landmarks.
      Ultrasound and electromyography (EMG) guidance will help us locate these muscles.

      The purpose of this study is to objectively measure functional improvement in patients with
      masticatory myofascial pain injected with lidocaine versus BTX-A. A pilot study enrolling 20
      patients is proposed. 20 patients will be randomized to receive either BTX-A or lidocaine
      injections into the bilateral temporalis, masseter, and medial and lateral pterygoid.
      Objective and subjective clinical parameters will be measured. These include pain at rest and
      with chewing, maximum non-assisted and assisted mouth opening, protrusive and laterotrusive
      jaw movements, subjective efficacy of treatment, and side-effects of treatment. Patients will
      be assessed at baseline, one week, one month, and three months after the procedure.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of eligible patients willing and able to participate
  </why_stopped>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Response as Assessed by &gt;20% Change From Baseline in the Jaw Functional Limitation Scale (JFLS) Global Score</measure>
    <time_frame>4 months</time_frame>
    <description>The JFLS contains 20 items that measure limitations across mastication, vertical jaw mobility, and verbal/emotional expression rated on a 0-10 scale where 0 = &quot;no limitation&quot; and 10 = &quot;severe limitation.&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Response as Assessed by &gt;20% Change From Baseline in the Jaw Functional Limitation Scale (JFLS) Global Score</measure>
    <time_frame>6 weeks</time_frame>
    <description>The JFLS contains 20 items that measure limitations across mastication, vertical jaw mobility, and verbal/emotional expression rated on a 0-10 scale where 0 = &quot;no limitation&quot; and 10 = &quot;severe limitation.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Response as Assessed by &gt;20% Change From Baseline in the Pressure Pain Threshold</measure>
    <time_frame>baseline, 4 months</time_frame>
    <description>measurements were obtained by placing examiner's index finger of the examiner on the area of the trigger point (hyperirritable areas on skeletal muscle with palpable taut bands of muscle fibers) and exerting pressure until there was whitening of the nail bed. Pressure pain levels were rated subjectively by the participant and coded numerically as mild (1), moderate (2) to severe (3).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Response as Assessed by &gt;20% Change From Baseline in Jaw Opening</measure>
    <time_frame>baseline, 4 months</time_frame>
    <description>maximum mandibular range of motion scores (measured as the maximum interincisal distance and compensating for occlusion)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Face Pain</condition>
  <arm_group>
    <arm_group_label>Lidocaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>lidocaine injection group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Botulinum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lidocaine</intervention_name>
    <description>1cc 1%</description>
    <arm_group_label>Lidocaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemodenervation</intervention_name>
    <description>botulinum toxin</description>
    <arm_group_label>Botulinum</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects are to have identifiable painful myofascial trigger points in the masseter,
             temporalis, and medial and lateral pterygoid muscles.

          -  Subjects will be examined by the principle investigators to determine if the
             individual is a suitable candidate for the study, based on active trigger points and
             willingness to participate in the study

        Exclusion Criteria:

          -  Pregnant woman will be excluded from participation as potential risk is noted in
             product label indications. Individuals over the age of 65 will be excluded per product
             label indications that reflect lack of data in individuals over age 65.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marisa Chang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Westwood Associates</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2009</study_first_submitted>
  <study_first_submitted_qc>October 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2009</study_first_posted>
  <results_first_submitted>August 29, 2016</results_first_submitted>
  <results_first_submitted_qc>November 2, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 29, 2016</results_first_posted>
  <last_update_submitted>November 2, 2016</last_update_submitted>
  <last_update_submitted_qc>November 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bruxism</keyword>
  <keyword>Myofascial pain</keyword>
  <keyword>EMG</keyword>
  <keyword>Ultrasound</keyword>
  <keyword>Masticatory myofascial face pain from bruxism and clenching</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Facial Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Botulinum Toxins</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lidocaine</title>
          <description>lidocaine injection group
lidocaine: 1cc 1%</description>
        </group>
        <group group_id="P2">
          <title>Botulinum</title>
          <description>chemodenervation: botulinum toxin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lidocaine</title>
          <description>lidocaine injection group
lidocaine: 1cc 1%</description>
        </group>
        <group group_id="B2">
          <title>Botulinum</title>
          <description>chemodenervation: botulinum toxin</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.14" lower_limit="38" upper_limit="76"/>
                    <measurement group_id="B2" value="44.7" lower_limit="24" upper_limit="65"/>
                    <measurement group_id="B3" value="49.82" lower_limit="24" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Response as Assessed by &gt;20% Change From Baseline in the Jaw Functional Limitation Scale (JFLS) Global Score</title>
        <description>The JFLS contains 20 items that measure limitations across mastication, vertical jaw mobility, and verbal/emotional expression rated on a 0-10 scale where 0 = &quot;no limitation&quot; and 10 = &quot;severe limitation.&quot;</description>
        <time_frame>4 months</time_frame>
        <population>participants who completed the 4-month follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Lidocaine</title>
            <description>lidocaine injection group
lidocaine: 1cc 1%</description>
          </group>
          <group group_id="O2">
            <title>Botulinum</title>
            <description>chemodenervation: botulinum toxin</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Response as Assessed by &gt;20% Change From Baseline in the Jaw Functional Limitation Scale (JFLS) Global Score</title>
          <description>The JFLS contains 20 items that measure limitations across mastication, vertical jaw mobility, and verbal/emotional expression rated on a 0-10 scale where 0 = &quot;no limitation&quot; and 10 = &quot;severe limitation.&quot;</description>
          <population>participants who completed the 4-month follow-up</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Response as Assessed by &gt;20% Change From Baseline in the Jaw Functional Limitation Scale (JFLS) Global Score</title>
        <description>The JFLS contains 20 items that measure limitations across mastication, vertical jaw mobility, and verbal/emotional expression rated on a 0-10 scale where 0 = &quot;no limitation&quot; and 10 = &quot;severe limitation.&quot;</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lidocaine</title>
            <description>lidocaine injection group
lidocaine: 1cc 1%</description>
          </group>
          <group group_id="O2">
            <title>Botulinum</title>
            <description>chemodenervation: botulinum toxin</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Response as Assessed by &gt;20% Change From Baseline in the Jaw Functional Limitation Scale (JFLS) Global Score</title>
          <description>The JFLS contains 20 items that measure limitations across mastication, vertical jaw mobility, and verbal/emotional expression rated on a 0-10 scale where 0 = &quot;no limitation&quot; and 10 = &quot;severe limitation.&quot;</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Response as Assessed by &gt;20% Change From Baseline in the Pressure Pain Threshold</title>
        <description>measurements were obtained by placing examiner’s index finger of the examiner on the area of the trigger point (hyperirritable areas on skeletal muscle with palpable taut bands of muscle fibers) and exerting pressure until there was whitening of the nail bed. Pressure pain levels were rated subjectively by the participant and coded numerically as mild (1), moderate (2) to severe (3).</description>
        <time_frame>baseline, 4 months</time_frame>
        <population>Participants completing the 4-month follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Lidocaine</title>
            <description>lidocaine injection group
lidocaine: 1cc 1%</description>
          </group>
          <group group_id="O2">
            <title>Botulinum</title>
            <description>chemodenervation: botulinum toxin</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Response as Assessed by &gt;20% Change From Baseline in the Pressure Pain Threshold</title>
          <description>measurements were obtained by placing examiner’s index finger of the examiner on the area of the trigger point (hyperirritable areas on skeletal muscle with palpable taut bands of muscle fibers) and exerting pressure until there was whitening of the nail bed. Pressure pain levels were rated subjectively by the participant and coded numerically as mild (1), moderate (2) to severe (3).</description>
          <population>Participants completing the 4-month follow-up</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Response as Assessed by &gt;20% Change From Baseline in Jaw Opening</title>
        <description>maximum mandibular range of motion scores (measured as the maximum interincisal distance and compensating for occlusion)</description>
        <time_frame>baseline, 4 months</time_frame>
        <population>Participants completing the 4-month follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Lidocaine</title>
            <description>lidocaine injection group
lidocaine: 1cc 1%</description>
          </group>
          <group group_id="O2">
            <title>Botulinum</title>
            <description>chemodenervation: botulinum toxin</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Response as Assessed by &gt;20% Change From Baseline in Jaw Opening</title>
          <description>maximum mandibular range of motion scores (measured as the maximum interincisal distance and compensating for occlusion)</description>
          <population>Participants completing the 4-month follow-up</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Lidocaine</title>
          <description>lidocaine injection group
lidocaine: 1cc 1%</description>
        </group>
        <group group_id="E2">
          <title>Botulinum</title>
          <description>chemodenervation: botulinum toxin</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>facial muscle weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Marisa Chang, MD</name_or_title>
      <organization>UCLA Neurology</organization>
      <phone>310-794-1870</phone>
      <email>marisachang@mednet.ucla.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

